|
|
|
|
| LEADER |
03476nma a2200961 u 4500 |
| 001 |
EB002052804 |
| 003 |
EBX01000000000000001196470 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220822 ||| eng |
| 020 |
|
|
|a 9783036510279
|
| 020 |
|
|
|a 9783036510262
|
| 020 |
|
|
|a books978-3-0365-1027-9
|
| 100 |
1 |
|
|a Turgeon, Jacques
|
| 245 |
0 |
0 |
|a Precision Medicine
|h Elektronische Ressource
|b Applied Concepts of Pharmacogenomics in Patients with Various Diseases and Polypharmacy
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2022
|
| 300 |
|
|
|a 1 electronic resource (170 p.)
|
| 653 |
|
|
|a genetics
|
| 653 |
|
|
|a personalized treatment
|
| 653 |
|
|
|a ulcerative colitis
|
| 653 |
|
|
|a pharmacoepigenomics
|
| 653 |
|
|
|a clinical pharmacogenetics
|
| 653 |
|
|
|a myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
|
| 653 |
|
|
|a fluoropyrimidine
|
| 653 |
|
|
|a pharmacogenetic test
|
| 653 |
|
|
|a CYP3A5
|
| 653 |
|
|
|a pharmacogenetics
|
| 653 |
|
|
|a glutathione S-transferase
|
| 653 |
|
|
|a n/a
|
| 653 |
|
|
|a Pharmaco-miR
|
| 653 |
|
|
|a CYP450
|
| 653 |
|
|
|a phenotype
|
| 653 |
|
|
|a miRNome
|
| 653 |
|
|
|a genotype
|
| 653 |
|
|
|a pharmacogenetic testing
|
| 653 |
|
|
|a 5-fluorouracil
|
| 653 |
|
|
|a fibromyalgia (FM)
|
| 653 |
|
|
|a liver transplant
|
| 653 |
|
|
|a data collection
|
| 653 |
|
|
|a pharmacokinetics
|
| 653 |
|
|
|a chronic low back pain (cLBP)
|
| 653 |
|
|
|a drug
|
| 653 |
|
|
|a orthotopic liver transplant
|
| 653 |
|
|
|a pharmacogene
|
| 653 |
|
|
|a pharmacogenomic
|
| 653 |
|
|
|a therapeutic drug monitoring
|
| 653 |
|
|
|a personalized medicine
|
| 653 |
|
|
|a tacrolimus
|
| 653 |
|
|
|a DPYD
|
| 653 |
|
|
|a pharmacogenomics
|
| 653 |
|
|
|a biomarker
|
| 653 |
|
|
|a genetic polymorphism
|
| 653 |
|
|
|a barriers to pharmacogenetics implementation
|
| 653 |
|
|
|a Crohn disease
|
| 653 |
|
|
|a Sub-Saharan Africa
|
| 653 |
|
|
|a busulfan
|
| 653 |
|
|
|a infliximab
|
| 653 |
|
|
|a polymorphism
|
| 653 |
|
|
|a limited sampling strategy
|
| 653 |
|
|
|a SM2miR
|
| 653 |
|
|
|a inflammatory bowel disease
|
| 653 |
|
|
|a gene expression
|
| 653 |
|
|
|a adverse drug reactions
|
| 653 |
|
|
|a Clinical and internal medicine / bicssc
|
| 653 |
|
|
|a minority
|
| 653 |
|
|
|a adalimumab
|
| 653 |
|
|
|a dihydropyrimidine dehydrogenase
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a repoDB
|
| 653 |
|
|
|a microRNA
|
| 653 |
|
|
|a ME/CFS Common Data Elements (CDEs)
|
| 700 |
1 |
|
|a Michaud, Veronique
|
| 700 |
1 |
|
|a Turgeon, Jacques
|
| 700 |
1 |
|
|a Michaud, Veronique
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-1027-9
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/5766
|7 0
|x Verlag
|3 Volltext
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/91133
|z DOAB: description of the publication
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 580
|
| 520 |
|
|
|a This colligated Special Issue of Pharmaceutics on Precision Medicine: Applied Concepts of Pharmacogenomics in Patients with Various Diseases and Polypharmacy offers to the reader a series of articles that describe the concept of Precision Medicine, discuss its implementation process and limitations, demonstrate its value by illustrating some clinical cases, and open the door to new and more sophisticated techniques and applications.
|